Financial Position - The company has $111.4 million in cash equivalents, including money market accounts, as of December 31, 2025[582]. - The company had $96.1 million in investment grade corporate and municipal bonds as of December 31, 2025[582]. - The company experienced a decline in cash equivalents from $102.1 million in 2024 to $111.4 million in 2025, indicating a growth in liquidity[582][583]. - The company maintains significant cash balances exceeding federally insured limits, which poses a normal business risk[584]. - As of December 31, 2025, the company had $610.4 million in long-term debt and finance leases, all with fixed interest rates or locked-in fixed rates through swap contracts[586]. Tax and Regulatory Risks - The company is subject to changes in tax laws, such as the 1% excise tax on stock repurchases and a 15% alternative minimum tax on adjusted financial statement income[468]. - The company is evaluating the impact of the OBBB Act on its financial position and results of operations[468]. - The company is subject to significant judgment in determining its worldwide provision for income taxes, which may lead to material differences in tax audits[469]. Market Risks - The company is exposed to market risks including investment risk, interest rate risk, and foreign currency exchange risk[580]. - The company is primarily exposed to interest rate risk through interest rate sensitive investments and credit facilities, but believes it is not subject to material risk with respect to short-term investments[585]. - The company's operations in France are exposed to market risk related to changes in foreign currency exchange rates due to sales contracts frequently denominated in euros[587]. Foreign Currency Exposure - A theoretical 10% unfavorable change in the exchange rate of the U.S. dollar against foreign currencies would result in approximately $0.1 million reduction of foreign currency gains and approximately $3.6 million reduction in other comprehensive income as of December 31, 2025[591]. - As of December 31, 2024, a theoretical 10% unfavorable change in the exchange rate would lead to approximately $1.2 million reduction of foreign currency gains and approximately $3.1 million reduction in other comprehensive income[592]. - The company's foreign subsidiaries had cash balances in foreign currencies amounting to $7.7 million and $6.6 million as of December 31, 2025 and 2024, respectively[592]. - The company may enter into derivative contracts to manage interest-rate exposures and achieve a balance between fixed- and floating-rate debt[585]. - The unrealized gains or losses from intercompany foreign currency transactions of a long-term investment nature are reported in other accumulated comprehensive income (loss)[589]. - The company's Chinese subsidiary maintains its books in Chinese yuan, which are remeasured into USD using current or historical exchange rates[588]. - The company is exposed to potential earnings effects from intercompany foreign currency assets and liabilities arising from normal trade receivables and payables[590]. Operational Risks - The company’s operating results may fluctuate significantly due to various factors, including the commercial success of key products and regulatory actions[475]. - The company recorded no declines in fair value of investments that are considered other than temporary as of December 31, 2025[581].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36869 PJT Partners Inc. (Exact name of Registrant as specified in its Charter) Delaware 36-4797143 (State or other jurisdiction of in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) | Cayman Islands 98-1480821 | | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-15950 FIRST BUSEY CORPORATION (Exact name of registrant as specified in its charter) Nevada 37-1078406 (State or other jurisdiction of incorporation of organization) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________ FORM 8-K __________________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2026 NuScale Power Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction Delaware 001-39736 98-1588588 (971) 371-1592 (Registrant's telephone number, including area code) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 MBIA Inc. (Exact name of Registrant as Specified in Its Charter) Registrant's Telephone Number, Including Area Code: 914 273-4545 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40297 N-able, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizati ...

Exhibit 99.1 QUARTERLY HIGHLIGHTS SELECTED FINANCIAL HIGHLIGHTS | | For the Quarter Ended | | | | | --- | --- | --- | --- | --- | | ($ in thousands, except per share information) | December 31, 2025 | | | September 30, 2025 | | Net investment income per share | $ | 0.49 | $ | 0.50 | | Net realized and unrealized gains (losses) per share 1 | ($ | 0.16) | ($ | 0.18) | | Earnings per share | $ | 0.33 | $ | 0.32 | | Regular dividend per share | $ | 0.50 | $ | 0.50 | 1 Amount shown may not correspond for the per ...

(Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(ad) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-K ___________________________________ For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission File Number 001-38953 The RealReal, Inc. (Exact name of Re ...